Lineage Cell Therapeutics, Inc. (LCTX) Stock Price

LCTXStock

$0.98−42.45%52W

Market Cap$247.42M

P/E—

PEG Ratio10.64

Div yield—

Beta1.66

LCTX Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)-48.38%

Price vs S&P 500 (4W)-1.81%

PEG Ratio10.64

VGM Score43.84

Book Value / Share (Quarterly)$0.24

P/TBV (Annual)29.94x

Revenue Growth (3Y)61.12%

Cash Flow / Share (Quarterly)$-0.10

Price vs S&P 500 (YTD)-53.35%

Gross Margin (TTM)94.11%

Net Profit Margin (TTM)-263.65%

EPS (TTM)$-0.14

10-Day Avg Trading Volume1.54M

EPS Excl Extra (TTM)$-0.14

Revenue Growth (5Y)33.57%

EPS (Annual)$-0.28

ROI (Annual)-142.39%

Gross Margin (Annual)92.50%

Net Profit Margin (5Y Avg)-506.99%

Cash / Share (Quarterly)$0.20

Revenue Growth QoQ (YoY)-58.44%

ROA (Last FY)-56.43%

Revenue Growth TTM (YoY)-37.15%

EBITD / Share (TTM)$-0.11

ROE (5Y Avg)-28.77%

Operating Margin (TTM)-285.11%

Cash Flow / Share (Annual)$-0.08

P/B Ratio4.06x

P/B Ratio (Quarterly)5.36x

Net Income / Employee (Annual)$-882,400

EV / Revenue (TTM)19.51x

Net Interest Coverage (TTM)-17.84x

ROA (TTM)-30.87%

EV / EBITDA (TTM)7.66x

EPS Incl Extra (Annual)$-0.28

Current Ratio (Annual)5.20x

Quick Ratio (Quarterly)6.44x

3-Month Avg Trading Volume1.42M

52-Week Price Return-42.45%

Revenue / Employee (TTM)$112,461,500,000

Tangible BV / Share (Quarterly)$0.12

P/S Ratio (Annual)27.66x

Asset Turnover (Annual)0.09x

52-Week High$2.09

Operating Margin (5Y Avg)-339.82%

EPS Excl Extra (Annual)$-0.28

CapEx CAGR (5Y)-20.81%

Tangible BV CAGR (5Y)-36.58%

26-Week Price Return-38.47%

Quick Ratio (Annual)4.99x

13-Week Price Return-15.66%

Total Debt / Equity (Annual)0.00x

Current Ratio (Quarterly)6.61x

Enterprise Value$210.11M

Revenue / Share Growth (5Y)23.45%

Asset Turnover (TTM)0.07x

Book Value / Share Growth (5Y)-19.58%

Revenue / Employee (Annual)$124,200

Inventory Turnover (Annual)7.40x

Pretax Margin (Annual)-260.28%

Cash / Share (Annual)$0.23

3-Month Return Std Dev54.40%

Gross Margin (5Y Avg)88.93%

Net Income / Employee (TTM)$-448,100

ROE (Last FY)-142.61%

Net Interest Coverage (Annual)-16.50x

EPS Basic Excl Extra (Annual)$-0.28

P/FCF (TTM)14.83x

Receivables Turnover (TTM)20.26x

Total Debt / Equity (Quarterly)0.00x

EPS Incl Extra (TTM)$-0.14

Receivables Turnover (Annual)0.58x

ROI (TTM)-71.04%

P/S Ratio (TTM)19.32x

Pretax Margin (5Y Avg)-535.76%

Revenue / Share (Annual)$0.05

Tangible BV / Share (Annual)$0.05

Free OCF CAGR (5Y)-38.10%

Price vs S&P 500 (52W)-57.98%

EPS Growth TTM (YoY)53.54%

Year-to-Date Return-41.42%

5-Day Price Return2.54%

EPS Normalized (Annual)$-0.28

ROA (5Y Avg)-22.63%

Net Profit Margin (Annual)-240.20%

Month-to-Date Return2.36%

Cash Flow / Share (TTM)$-0.13

EBITD / Share (Annual)$-0.16

Operating Margin (Annual)-276.50%

LT Debt / Equity (Annual)0.11x

ROI (5Y Avg)-25.56%

LT Debt / Equity (Quarterly)0.14x

EPS Basic Excl Extra (TTM)$-0.14

P/TBV (Quarterly)11.18x

P/B Ratio (Annual)8.63x

Inventory Turnover (TTM)7.40x

Pretax Margin (TTM)-284.20%

Book Value / Share (Annual)$0.18

Price vs S&P 500 (13W)-18.35%

Beta1.66x

P/FCF (Annual)262.32x

Revenue / Share (TTM)$0.05

ROE (TTM)-71.14%

52-Week Low$0.88

vGradeC

gGradeD

mGradeC

vgmGradeC

LCTX Earnings Surprise History

Quarter	Report date	EPS estimate	EPS actual	Surprise
Q2 2026	Aug 6, 2026	-$0.03	$0.01	+133.33%(+$0.04)
Q4 2025	Mar 5, 2026	-$0.04	$0.00	+100.00%(+$0.04)
Q3 2025	Nov 6, 2025	-$0.03	-$0.13	-358.88%(-$0.10)
Q2 2025	Aug 12, 2025	-$0.03	-$0.13	-358.88%(-$0.10)

LCTX Analyst Recommendations

Jun 2026

Jul 2026

Aug 2026

Sep 2026

4.08

Industry Peers — Biological Products(186)

Symbol	Value Score	Growth Score	Momentum Score	P/S Ratio (TTM)	Revenue Growth TTM (YoY)	Gross Margin (TTM)	EPS Growth (5Y)	Price
LCTXLineage Cell Therapeutics, Inc.	C	D	C	19.3x	-37.1%	94.1%	—	$0.98
AMGNAmgen Inc	D	C	A	6.1x	9.1%	74.3%	2.9%	$432.49
GILDGilead Sciences Inc	C	B	A	6.4x	5.5%	79.6%	133.6%	$156.19
MRNAModerna, Inc. Common Stock	F	C	A	39.1x	-27.6%	36.4%	—	$218.01
ARGXargenx SE American Depositary Shares	D	A	B	6.6x	165.2%	89.8%	—	$819.14
RVMDRevolution Medicines, Inc. Common Stock	F	—	B	3296.2x	—	—	—	$177.96
BIIBBiogen Inc. Common Stock	C	D	A	3.4x	0.3%	74.0%	-18.8%	$232.65
BNTXBioNTech SE American Depositary Share	C	C	C	7.6x	-11.8%	79.2%	—	$87.71
EXELExelixis Inc	C	B	A	6.3x	9.2%	96.5%	31.1%	$62.23
HALOHalozyme Therapeutics, Inc.	D	B	A	8.3x	41.1%	82.4%	22.9%	$121.84
NBIXNeurocrine Biosciences Inc	C	B	B	4.1x	34.4%	98.0%	2.3%	$135.71
TECHBio-Techne Corp.	D	C	B	9.4x	-0.4%	66.2%	6.0%	$72.57
RGENRepligen Corp	F	C	A	14.2x	16.5%	53.8%	-4.9%	$175.42
APGEApogee Therapeutics, Inc. Common Stock	—	—	A	—	—	—	—	$135.07
PCVXVaxcyte, Inc. Common Stock	—	—	B	—	—	—	—	$63.62
IBRXImmunityBio, Inc. Common Stock	F	A	A	58.7x	192.9%	99.3%	—	$9.18
QGENQIAGEN N.V.	C	C	B	4.5x	3.0%	62.5%	4.2%	$46.13
KRYSKrystal Biotech, Inc. Common Stock	D	B	B	21.3x	22.6%	94.6%	—	$316.58
TWSTTwist Bioscience Corporation Common Stock	D	B	A	20.2x	19.2%	52.0%	—	$132.75
KYMRKymera Therapeutics, Inc. Common Stock	F	B	B	83.0x	134.8%	—	—	$104.78
IOVAIovance Biotherapeutics, Inc. Common Stock	D	B	A	19.0x	34.5%	48.4%	—	$13.62
IMVTImmunovant, Inc. Common Stock	—	—	C	—	—	—	—	$26.73
KODKodiak Sciences Inc Common Stock	—	—	A	—	—	—	—	$85.75
CGONCG Oncology, Inc. Common stock	F	A	B	851.8x	1030.3%	-85.2%	—	$59.85
SRRKScholar Rock Holding Corporation Common Stock	F	—	C	102.7x	—	—	—	$39.90
CRSPCRISPR Therapeutics AG	D	B	B	355.6x	-64.8%	—	—	$49.25
ADPTAdaptive Biotechnologies Corporation Common Stock	D	B	B	12.4x	50.1%	75.6%	—	$24.02
RLAYRelay Therapeutics, Inc. Common Stock	F	D	B	344.7x	23.9%	—	—	$16.28
TARSTarsus Pharmaceuticals, Inc. Common Stock	D	A	B	5.5x	105.2%	93.3%	—	$68.07
DNLIDenali Therapeutics Inc. Common Stock	F	—	C	781.1x	—	—	—	$17.61
BEAMBeam Therapeutics Inc. Common Stock	D	B	C	15.5x	158.9%	—	—	$23.47
ADMAADMA Biologics, Inc.	C	C	B	4.7x	8.0%	64.7%	—	$10.68
VCELVericel Corporation	D	B	B	6.7x	22.9%	74.6%	38.9%	$40.13
BCRXBioCryst Pharmaceuticals Inc	B	A	B	2.1x	68.7%	97.8%	—	$7.79
RXRXRecursion Pharmaceuticals, Inc. Class A Common Stock	D	C	C	33.9x	-15.1%	3.5%	—	$3.46
NVAXNovavax Inc	C	D	B	4.5x	-61.6%	79.2%	—	$11.26
ALVOAlvotech Ordinary Shares	D	D	B	3.9x	-12.1%	60.7%	—	$5.00
MESOMesoblast Limited American Depositary Shares	D	A	C	14.6x	599.2%	86.1%	—	$13.28
VIRVir Biotechnology, Inc. Common Stock	B	B	B	5.6x	1496.1%	100.0%	—	$9.96
MAZEMaze Therapeutics, Inc. Common Stock	—	A	B	—	700.0%	—	—	$27.53
IMCRImmunocore Holdings plc American Depositary Shares	D	B	B	3.5x	20.9%	98.9%	—	$29.40
COAGHemab Therapeutics Holdings, Inc. Common Stock	—	—	C	—	—	—	—	$30.07
INBXInhibrx Biosciences, Inc. Common Stock	D	C	A	944.3x	550.0%	—	—	$89.83
TSHATaysha Gene Therapies, Inc. Common Stock	D	C	D	120.7x	-32.3%	—	—	$3.62
IMTXImmatics N.V. Ordinary Shares	C	C	C	21.5x	-68.0%	—	—	$6.73
REPLReplimune Group, Inc.	—	—	B	—	—	—	—	$10.86
VORVor Biopharma Inc. Common Stock	—	—	C	—	—	—	—	$18.03
MGTXMeiraGTx Holdings plc Ordinary Shares	C	A	C	2.2x	948.4%	98.0%	—	$9.28
SLBTSL Science Holding Limited Ordinary Shares	—	—	D	—	—	—	—	$1.53
CGEMCullinan Therapeutics, Inc. Common Stock	—	—	C	—	—	—	—	$12.93
GLUEMonte Rosa Therapeutics, Inc. Common Stock	D	F	D	28.9x	-83.9%	—	—	$9.74

About Lineage Cell Therapeutics, Inc.

Lineage Cell Therapeutics is a clinical-stage biotechnology company developing cell replacement and cell/drug delivery therapies for degenerative diseases. Key pipeline candidates include OpRegen for age-related macular degeneration, OPC1 for spinal cord injuries, VAC2 for non-small cell lung cancer, and cell therapies for hearing and vision loss.